Cargando…

Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

JNJ-Q2 is a novel, fifth-generation fluoroquinolone that has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsible for acute bacterial skin and skin structure inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Travis M, Johnson, Steven W, DiMondi, V Paul, Wilson, Dustin T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908938/
https://www.ncbi.nlm.nih.gov/pubmed/27354817
http://dx.doi.org/10.2147/IDR.S105620
_version_ 1782437771431903232
author Jones, Travis M
Johnson, Steven W
DiMondi, V Paul
Wilson, Dustin T
author_facet Jones, Travis M
Johnson, Steven W
DiMondi, V Paul
Wilson, Dustin T
author_sort Jones, Travis M
collection PubMed
description JNJ-Q2 is a novel, fifth-generation fluoroquinolone that has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsible for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), such as Staphylococcus aureus and Streptococcus pneumoniae. JNJ-Q2 also has been shown to have a higher barrier to resistance compared to other agents in the class and it remains highly active against drug-resistant organisms, including methicillin-resistant S. aureus, ciprofloxacin-resistant methicillin-resistant S. aureus, and drug-resistant S. pneumoniae. In two Phase II studies, the efficacy of JNJ-Q2 was comparable to linezolid for ABSSSI and moxifloxacin for CABP. Furthermore, JNJ-Q2 was well tolerated, with adverse event rates similar to or less than other fluoroquinolones. With an expanded spectrum of activity and low potential for resistance, JNJ-Q2 shows promise as an effective treatment option for ABSSSI and CABP. Considering its early stage of development, the definitive role of JNJ-Q2 against these infections and its safety profile will be determined in future Phase III studies.
format Online
Article
Text
id pubmed-4908938
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49089382016-06-28 Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections Jones, Travis M Johnson, Steven W DiMondi, V Paul Wilson, Dustin T Infect Drug Resist Review JNJ-Q2 is a novel, fifth-generation fluoroquinolone that has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsible for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), such as Staphylococcus aureus and Streptococcus pneumoniae. JNJ-Q2 also has been shown to have a higher barrier to resistance compared to other agents in the class and it remains highly active against drug-resistant organisms, including methicillin-resistant S. aureus, ciprofloxacin-resistant methicillin-resistant S. aureus, and drug-resistant S. pneumoniae. In two Phase II studies, the efficacy of JNJ-Q2 was comparable to linezolid for ABSSSI and moxifloxacin for CABP. Furthermore, JNJ-Q2 was well tolerated, with adverse event rates similar to or less than other fluoroquinolones. With an expanded spectrum of activity and low potential for resistance, JNJ-Q2 shows promise as an effective treatment option for ABSSSI and CABP. Considering its early stage of development, the definitive role of JNJ-Q2 against these infections and its safety profile will be determined in future Phase III studies. Dove Medical Press 2016-06-07 /pmc/articles/PMC4908938/ /pubmed/27354817 http://dx.doi.org/10.2147/IDR.S105620 Text en © 2016 Jones et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Jones, Travis M
Johnson, Steven W
DiMondi, V Paul
Wilson, Dustin T
Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
title Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
title_full Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
title_fullStr Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
title_full_unstemmed Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
title_short Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
title_sort focus on jnj-q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908938/
https://www.ncbi.nlm.nih.gov/pubmed/27354817
http://dx.doi.org/10.2147/IDR.S105620
work_keys_str_mv AT jonestravism focusonjnjq2anovelfluoroquinoloneforthemanagementofcommunityacquiredbacterialpneumoniaandacutebacterialskinandskinstructureinfections
AT johnsonstevenw focusonjnjq2anovelfluoroquinoloneforthemanagementofcommunityacquiredbacterialpneumoniaandacutebacterialskinandskinstructureinfections
AT dimondivpaul focusonjnjq2anovelfluoroquinoloneforthemanagementofcommunityacquiredbacterialpneumoniaandacutebacterialskinandskinstructureinfections
AT wilsondustint focusonjnjq2anovelfluoroquinoloneforthemanagementofcommunityacquiredbacterialpneumoniaandacutebacterialskinandskinstructureinfections